Filing Details
- Accession Number:
- 0001346302-21-000002
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-01-12 16:02:36
- Reporting Period:
- 2021-01-11
- Accepted Time:
- 2021-01-12 16:02:36
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1346302 | Xeris Pharmaceuticals Inc | XERS | Pharmaceutical Preparations (2834) | 203352427 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1744027 | Steven Prestrelski | C/O Xeris Pharmaceuticals, Inc. 180 N. Lasalle Street, Suite 1600 Chicago IL 60601 | Chief Scientific Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2021-01-11 | 10,000 | $5.72 | 416,824 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- $5.7244 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.50 to $5.88, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Billionaire Hedge Funds
